Protopy

Procedural steps taken and scientific information after the authorisation
Changes made after 01/10/2003

For procedures finalised before 01/10/2003, please refer to module 8A

MAJOR CHANGES[1]

No	Scope	Opinion issued on	Commission Decision Issued/ amended on	Product Information affected[2]	Summary
II/0028	Update of Summary of Product Characteristics and Package Leaflet Update of section 5.2 of the SPC to include information on tacrolimus blood concentrations in infants from age of 5 months and to specify the approved strengths of tacrolimus ointment used in the pharmacokinetic studies in adults and children following the assessment of a post approval commitment. Amendment of section 5.3 to correct a mistake in the route of administration used in a reproduction toxicity study.	22/03/2007	03/05/2007	SPC, PL	Further to the CHMP assessment of the pharmacokinetic study FG-506-06-32 which characterised the PK profile of 0.03 % tacrolimus in paediatric patients aged 3-24 months, the MAH amended Section 5.2 of the SPC to reflect the information on the absorption in infants from age of 5 months, as requested by the CHMP. The MAH has also amended Section 5.3 to correct a mistake with respect to the route of administration in the male reproductive toxicity study. The Package leaflet has been amended to include the two new Member States, Bulgaria and Romania, to the list of local representatives. The contact details for some local representatives have also been updated.
R/0027	Renewal of the marketing authorisation	21/09/2006	20/11/2006	SPC, Labelling, PL	Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP was of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit/risk profile of Protopy continues to be favourable.

[1] Major changes e.g. Type II variations, Annex II applications, Renewals and Annual Reassessments
[2] SPC (Summary of Product Characteristics), Labelling, PL (Package Leaflet)

					The CHMP was also of the opinion that the renewal can be granted with unlimited validity.
EMEA/H/A-18/662	Pursuant to Article 20 of Regulation (EC) No 726/2004 of 31 March 2004 (corresponding to Article 18 of Council Regulation (ECC) No 2309/93 of 22 July 1993), the European Commission requested on 21 April 2005 the opinion of the CHMP on the benefit/risk profile of Protopy in view of the potential risk of malignancies.	23/03/2006	12/06/2006	SPC, PL	Please refer to the Scientific Conclusions: Protopy EMEA/H/A-18/662
II/0022	Update of Summary of Product Characteristics and Package Leaflet The Marketing Authorisation Holder applied for an update of section 4.8 (Undesirable effects) of the Summary of Product Characteristics and section 4 of the Package Leaflet to include information on rosacea following the assessment of the 5th PSUR.	21/04/2005	10/06/2005	SPC	Based on the assessment of the 5th Periodic Safety Update Report the Marketing Authorisation Holder applied to update section 4.8 of the Summary of Product Characteristics to state that the adverse reaction, rosacea, has been reported after marketing. This information has also been included in section 4 of the Package Leaflet.
II/0017	Update of Summary of Product Characteristics	03/06/2004	02/08/2004	SPC	This variation concerns an update of section 4.2 of the Summary of Product Characteristics to amend the wording of the current prescription restriction from "Protopic should only be prescribed by dermatologists and physicians with extensive experience in the treatment of atopic dermatitis with immunomodulating therapy" to "Protopic should be prescribed by physicians with experience in the treatment of atopic dermatitis". The list of local representatives has also been updated to include the local representatives in the Accession Countries in the package leaflet.

II/0016	Update of Summary of Product Characteristics	03/06/2004	02/08/2004	SPC	This variation concerns an update of section 5.2 (Pharmacokinetic properties) of the Summary of Product Characteristics to include further information on the distribution of tacrolimus ointment following topical application.
II/0015	Update of Summary of Product Characteristics and Package Leaflet	03/06/2004	02/08/2004	SPC, PL	The MAH applied for changes to the Summary of Product Characteristics and the Package Leaflet following the switch from COSTART terminology to MedDRA. New terms included represented the higher specificity of the MedDRA terminology and the changes reflected the change in terminology rather than a change in the safety profile.
II/0014	Update of Summary of Product Characteristics	03/06/2004	02/08/2004	SPC	This variation concerns an update of section 5.1 (Pharmacodynamic properties) of the Summary of Product Characteristics to include the results of three active comparator clinical studies.
II/0013	Update of Summary of Product Characteristics	03/06/2004	02/08/2004	SPC	This variation concerns an update of section 4.4 (Special warnings and special precautions for use) of the Summary of Product Characteristics following long-term experience for up to 4 years with consequential changes to section 5.1 (Pharmacodynamic properties) of the Summary of Product Characteristics.
II/0012	Update of Summary of Product Characteristics and Package Leaflet	03/06/2004	02/08/2004	SPC, PL	The Marketing Authorisation Holder applied for an update of section 4.2 (Posology) of the SPC and of section 3 (How to use Protopic) of the Package Leaflet in order to delete the 3-week restriction on treatment duration for 0.1% tacrolimus twice daily treatment.

II/0011	Update of or change(s) to the pharmaceutical documentation	26/02/2004	01/03/2004		The MAH applied for changes to the manufacturing method of the active substance.

MINOR CHANGES[3]

No	Scope	Product Information affected[2]	Date[4]
IA/0026	04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)		24/02/2006
IA/0025	05_Change in the name and/or address of a manufacturer of the finished product	PL	19/10/2005
IA/0024	01_Change in the name and/or address of the marketing authorisation holder 05_Change in the name and/or address of a manufacturer of the finished product	SPC, Labelling, PL	09/09/2005
IA/0023	05_Change in the name and/or address of a manufacturer of the finished product		19/07/2005
IB/0021	10_Minor change in the manufacturing process of the active substance		10/03/2005
IA/0020	13_a_Change in test proc. for active substance - minor change		10/02/2005
IA/0019	38_a_Change in test procedure of finished product - minor change to approved test procedure		29/11/2004
N/0018	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	Labelling, PL	16/11/2004
IA/0010	06_a_Change in ATC code: Medicinal products for human use	SPC	04/12/2003
IA/0009	04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)		26/11/2003
IA/0008	13_a_Change in test proc. for active substance - minor change		26/11/2003

[3] Minor changes e.g. Type I variations and Notifications
[4] Date of entry into force of the change